Do Not Buy NeuroSense (NRSN) Stock Now, Here is Why

By over 300% NeuroSense (Nasdaq: NRSN) is jumping on more than 85 million shares. Under $2 NRSN is quickly becoming over $6 after announcing the company receives FDA clearance to start a study pharmacokinetic study of PrimeC in healthy adult subjects. The PrimeC drug is to be used for neuro-related issues of humans.

Today the long-term holding investors of NRSN are crazily happy while short squeeze players are also enjoying the quick returns. If you just saw the stock soaring now you better avoid it. Tomorrow it will make corrections after the gamblers start selling. We will see after a few hours NRSN will be trading near the $5 mark. Next week it may dip further to $4.00.

nrsn stock